Dark

RDUS
Radius Recycling, Inc. Class A Common Stock
stock NASDAQ

Inactive

Jul 10, 2025

30.00USD+0.033%(+0.01)1,720,208

Pre-market

0.00USD-100.000%(-29.99)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 20, 2022

07:50AM EST Radius Pharmaceuticals Filed U.S. Patent Application #20220016052 'METHODS FOR TREATING CANCER IN MODELS HARBORING ESR1 MUTATIONS' Benzinga

Jan 13, 2022

11:48AM EST Radius Health Says Fires ~20% Of Non-Sales Personnel Benzinga

09:00AM EST -- Completion of three pivotal trials in 2021 enables restructuring of the operating infrastructure -- Non-Sales headcount reduced by approximately 20% -- Reductions focused on areas that supported abaloparatide clinical and regulatory activities -- Company to provide Q4 & FY 2021 results and 2022 outlook during earnings on February 24 GlobeNewswire Inc

Dec 23, 2021

10:41AM EST FDA Approves Update On Radius Health's Tymlos label Benzinga

08:31AM EST Radius Health Offers Update On TYMLOS Label: 'FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021' Benzinga

08:30AM EST -- FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021 -- The boxed warning had referred to the potential risk of osteosarcoma -- Action follows review of long-term post-marketing data for TYMLOS and PTH class of drugs GlobeNewswire Inc

Dec 20, 2021

08:32AM EST Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights Board of Directors as an independent director, effective December 15, 2021. GlobeNewswire Inc

Dec 16, 2021

05:47AM EST Radius Health 10%+ Owner David Efraim Rosen Reported Purchase of 462,238 @ Avg Price of $6.90/Share in Form 4 Filing on Wednesday Benzinga

Dec 10, 2021

12:41PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021 Benzinga

08:15AM EST Morgan Stanley Downgrades Radius Health to Underweight, Lowers Price Target to $7 Benzinga

07:51AM EST 10 Biggest Price Target Changes For Friday Benzinga

05:11AM EST Goldman Sachs Downgrades Radius Health to Neutral, Lowers Price Target to $12 Benzinga

Dec 9, 2021

09:45PM EST SVB Leerink Maintains Market Perform on Radius Health, Lowers Price Target to $20 Benzinga

09:45PM EST HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $10 Benzinga

09:38PM EST Mid-Afternoon Market Update: Nasdaq Rises 70 Points; Stitch Fix Shares Slide Benzinga

Dec 8, 2021

12:08PM EST Mid-Day Market Update: Photronics Rises Following Upbeat Q4 Results; Radius Health Shares Slide Benzinga

10:20AM EST Radius Health Highlights EMERALD Trial Results For Elacestrant Presented At San Antonio Breast Cancer Symposium: Trial Met Both Primary Endpoints Benzinga

10:16AM EST Mid-Morning Market Update: Markets Mixed; United Natural Foods Beats Q1 Views Benzinga

10:15AM EST Positive EMERALD Trial Results for Elacestrant Presented at San GlobeNewswire Inc

09:04AM EST Radius Announces wearABLe Trial Evaluating Abaloparatide Transdermal System Did Not Meet Primary Endpoint Benzinga

09:00AM EST Radius Announces Results from the wearABLe Trial Evaluating GlobeNewswire Inc

09:00AM EST Radius Health, Inc. (Radius or the Company) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below: GlobeNewswire Inc

Nov 11, 2021

08:30AM EST Radius Health, Inc. (Radius or the Company) (NASDAQ: RDUS) today announced that management will participate in the Stifel 2021 Virtual Healthcare Conference, including a fireside chat at 8:40 a.m. ET on Tuesday, November 16, 2021, followed by investor meetings. GlobeNewswire Inc

Nov 9, 2021

01:29PM EST What 5 Analyst Ratings Have To Say About Radius Health Benzinga

12:03PM EST SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $30 Benzinga

11:27AM EST HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $23 Benzinga

Nov 8, 2021

08:27AM EST Radius Health Q3 EPS $(0.32) Misses $(0.24) Estimate, Sales $56.81M Miss $61.27M Estimate Benzinga

08:00AM EST Radius Health, Inc.: Third Quarter 2021 Results GlobeNewswire Inc

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 5, 2021

11:29AM EDT Earnings Outlook For Radius Health Benzinga

Oct 21, 2021

01:15PM EDT In a release issued under the same headline yesterday, Oct. 20, by Radius Health, Inc. (NASDAQ: RDUS), please note that the dial-in numbers were listed incorrectly. The correct dial-in numbers are (866) 323-7965 for domestic calls and (346) 406-0961 for international calls. The conference ID remains the same,9322858. The corrected release appears below: GlobeNewswire Inc

12:57PM EDT Analyst Ratings For Radius Health Benzinga

12:11PM EDT SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $29 Benzinga

12:11PM EDT HC Wainwright & Co. Maintains Neutral on Radius Health, Raises Price Target to $26 Benzinga

12:10PM EDT Mid-Afternoon Market Update: Nasdaq Turns Lower; Sesen Bio Shares Surge Benzinga

Oct 20, 2021

03:00PM EDT Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a company update. GlobeNewswire Inc

12:18PM EDT Mid-Day Market Update: Healthcare Services Drops After Q3 Results; Radius Health Shares Jump Benzinga

10:32AM EDT Mid-Morning Market Update: Markets Open Higher; Verizon Posts Upbeat Earnings Benzinga

08:33AM EDT Radius Health, Menarini Group Report Phase 3 Topline Results From EMERALD Trial For Elacestrant In Breast Cancer: 'Study met both primary endpoints in patients with ER+/HER2- advanced or mBC' Benzinga

08:30AM EDT Menarini Group and Radius Health Announce Positive Phase 3 Topline GlobeNewswire Inc

Oct 18, 2021

09:11AM EDT Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company remains on track for an sNDA submission in the first quarter of 2022. RTTNews

08:48AM EDT Radius Announces ATOM Phase 3 Study Of TYMLOS Met Primary And Secondary Endpoints Benzinga

08:38AM EDT Radius Health Announces Positive Topline Results From ATOM Study RTTNews

08:30AM EDT Radius Announces Positive Phase 3 Topline Results for GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT Morgan Stanley Maintains Equal-Weight on Radius Health, Lowers Price Target to $18 Benzinga

Sep 22, 2021

08:00AM EDT -- TYMLOS label: significant update to the Mechanism of Action (MOA) section -- Label change aligns with strategic focus on postmenopausal women at high risk of fracture -- Danielle Holtschlag joins as Head of Sales, bringing 20 years of experience to the team -- Added ~3,000 new TYMLOS patients throughout July and August, up 13% year-over-year GlobeNewswire Inc

Sep 7, 2021

11:30AM EDT Radius Health Earnings Perspective: Return On Capital Employed Benzinga

Aug 6, 2021

06:16AM EDT HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $19 Benzinga

05:54AM EDT SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $26 Benzinga

Aug 5, 2021

07:34AM EDT Radius Health Q2 EPS $(0.22) Beats $(0.33) Estimate, Sales $51.80M Up From $50.11M YoY Benzinga

07:00AM EDT Radius Health, Inc.: Second Quarter and Year-to-Date Results GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Jul 27, 2021

11:13AM EDT CORRECTION: Radius Health Ticker Is 'RDUS' Benzinga

11:13AM EDT Radius Health Says Added 5,000+ New TYMLOS Patients In Q2 Benzinga

Jul 23, 2021

11:12AM EDT CORRECTION: Radius Health Announces Plans for Global Prader-Willi GlobeNewswire Inc

09:27AM EDT Radius Health Publishes Study Titled 'RWE Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women' To ClinicalTrials.Gov, Study Not Yet Recruiting Benzinga

Jul 22, 2021

09:02AM EDT Radius Health Announces Plans For Global Prader-Willi Syndrome Pivotal Study Benzinga

Jul 20, 2021

05:11PM EDT Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update. GlobeNewswire Inc

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

Jun 2, 2021

08:16AM EDT Radius Health Provides Business Update; Says TYMLOS Saw 'Modest Growth' Benzinga

08:15AM EDT Radius Health Business Update GlobeNewswire Inc

May 18, 2021

10:27AM EDT Morgan Stanley Maintains Equal-Weight on Radius Health, Raises Price Target to $20 Benzinga

May 10, 2021

06:57AM EDT SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $24 Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

06:38AM EDT Radius Health Q1 EPS $(0.34) Beats $(0.41) Estimate, Sales $56.26M Miss $60.38M Estimate Benzinga

06:30AM EDT Radius Health, Inc.: First Quarter 2021 Results GlobeNewswire Inc

04:12AM EDT Earnings Scheduled For May 7, 2021 Benzinga

May 6, 2021

10:15AM EDT Radius Health's Earnings: A Preview Benzinga

Apr 22, 2021

08:18AM EDT Radius Health Announces US TYMLOS Patient Growth Increased By 14% QoQ Benzinga

08:15AM EDT Radius Health Business Update GlobeNewswire Inc

Apr 20, 2021

04:30PM EDT Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update. GlobeNewswire Inc

Mar 30, 2021

07:17AM EDT Radius Global Infrastructure FY20 Sales $20.1M, Up 36% YoY Benzinga

Mar 25, 2021

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 24, 2021

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

08:08AM EDT Radius Health Says Teijin Pharma's Ostabaro Approved For Treatment Of Male And Female OP Patients At High Risk Of Fracture In Japan Benzinga

08:00AM EDT Radius Health Provides Update on Abaloparatide GlobeNewswire Inc

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

01:31AM EDT AZN's COVID-19 Jab Shows 79% Efficacy, ZEAL Wins FDA RTTNews

Mar 22, 2021

07:39AM EDT Goldman Sachs Assumes Radius Health at Buy, Announces Price Target of $33 Benzinga

Mar 3, 2021

04:23PM EST Radius Health Eliminates Approximately 2.3M Shares Of Potential Future Dilution Upon Conversion Of Notes Benzinga

04:22PM EST Radius Health Announces A $175M Financing Transaction Benzinga

04:22PM EST Radius Health Reaffirms FY21 Guidance Benzinga

04:15PM EST Radius Health, Inc. Announces $175 Million Financing Transaction GlobeNewswire Inc

Mar 1, 2021

08:05AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:39AM EST SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $23 Benzinga

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

07:25AM EST Radius Health Q4 EPS $(0.23) Beats $(0.42) Estimate, Sales $62.78M Beat $59.86M Estimate Benzinga

07:00AM EST Radius Health, Inc.: Fourth Quarter and Full Year Results GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 24, 2021

07:47AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

06:25AM EST HC Wainwright & Co. Maintains Neutral on Radius Health, Raises Price Target to $25 Benzinga

Feb 17, 2021

08:30AM EST Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021. GlobeNewswire Inc

Feb 16, 2021

08:30AM EST Radius Health(Nasdaq: RDUS) announced today that it will release its fourth quarter financial results onThursday, February 25, 2021. The Company will host a conference call and live audio webcast at8:30 a.m. ETthat day to discuss the results and provide a company update. GlobeNewswire Inc

Feb 12, 2021

12:35PM EST Radius Health, Inc. Provides Abaloparatide Business Update (Full Statement) Benzinga

12:33PM EST Radius Health, Inc. Provides Abaloparatide Business Update GlobeNewswire Inc

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 7, 2021

11:56AM EST Citigroup Maintains Buy on Radius Health, Raises Price Target to $30 Benzinga

08:02AM EST 10 Biggest Price Target Changes For Thursday Benzinga

06:32AM EST SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $20 Benzinga

Jan 6, 2021

12:00PM EST Radius Health, Inc.(Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39thAnnualJ.P. Morgan Healthcare ConferenceonWednesday, January 13 at 9:10 a.m. EST. GlobeNewswire Inc

06:02AM EST Radius Health, Inc. Announces Acquisition Of Benuvia Therapeutics Inc.'s RAD011 Cannabidiol Oral Solution For $12.5M With Additional $15M To Be Paid Contingent On The Successful Conclusion Of PWS Development Milestones Benzinga

06:00AM EST Radius Health, Inc. Announces Acquisition of Orphan Disease Program GlobeNewswire Inc

Jan 5, 2021

09:03AM EST Endo International plc (ENDP) said Tuesday that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. RTTNews

08:39AM EST Endo Ventures Enters Licensing Agreement For Paladin Labs To Commercialize Abaloparatide In Canada RTTNews

08:37AM EST Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize PR Newswire

08:23AM EST Radius Health Enters Definitive Agreements With Endo Ventures For Abaloparatide RTTNews

08:22AM EST Radius Health Announces Commercial Agreement With Paladin Labs For Abaloparatide in Canada Benzinga

08:15AM EST -- Agreement incorporates TYMLOS and abaloparatide-TD -- Consideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royalties -- Key first step in expanding the global footprint for the abaloparatide asset beyond the U.S. and Japan; a key focus area for the company for 2021 GlobeNewswire Inc

Jan 4, 2021

04:30PM EST Radius Health, Inc.(Radius or the Company) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the Companys board of directors. Ms. Sanders and Dr. von Eschenbach will fill vacancies created by the departures of Jessica Hopfield, Ph.D. and Tony Rosenberg, who stepped down from the board on December 31, 2020 after years of service. GlobeNewswire Inc

Dec 15, 2020

09:13AM EST Radius Health Offers Update On Commercial Progress, Research, Talent Benzinga

09:00AM EST -- Continued growth in net new patients for the month of November 2020 -- Company is on-track for record quarter in net revenue for TYMLOS-SC -- Research Agreement reached with MGH in October 2020 -- Hired Head of Clinical Development for the abaloparatide molecule GlobeNewswire Inc

Nov 5, 2020

08:01AM EST Radius Health Q3 Adj. EPS $0.15 Beats $(0.21) Estimate, Sales $77.83M Miss $78.38M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 22, 2020

08:04AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

06:45AM EDT HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $22 Benzinga

Oct 21, 2020

08:15AM EDT Radius Health, Inc.: Progress Since May 2020 GlobeNewswire Inc

Oct 20, 2020

04:15PM EDT Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update. GlobeNewswire Inc

Oct 6, 2020

04:30PM EDT Radius Health, Inc.(Radius or the Company) (Nasdaq: RDUS) today announced that Peter A. Schwartzman is joining the company as Vice President in the newly formed Capital, Strategy and Transactions (CST) Group. Peter, as part of the group, will report to Kelly Martin, CEO of Radius. GlobeNewswire Inc

Oct 1, 2020

09:03AM EDT Radius Health Reports Will Divest Its RAD 140 Program To Ellipses Pharma, No Terms Disclosed Benzinga

08:45AM EDT -- Business development step enables molecule to move forward -- Program progression will be at no financial risk to Radius -- Reinforces Radiusfocus on execution of core business GlobeNewswire Inc

Sep 25, 2020

06:06AM EDT Radius Health Reports Target Enrollment Milestone Reached For Phase 3 EMERALD Study Of Elacestrant Benzinga

05:55AM EDT Radius Health : Target Enrollment Milestone Reached In Phase 3 EMERALD Study RTTNews

05:52AM EDT Radius Health & Menarini Group Provide Elacestrant Update PR Newswire

Sep 24, 2020

04:25PM EDT Radius Health & Menarini Group Announces The Its EMERALD Phase 3 Study Reached Its Target Enrollment Milestone And The Life Cycle Planning Is Advancing In Parallel With The Current Phase 3 Monotherapy Program Benzinga

04:15PM EDT -- Target enrollment milestone reached in the Phase 3 EMERALD study -- Life cycle planning advancing in parallel with current Phase 3 monotherapy program GlobeNewswire Inc

08:22AM EDT Radius Health: Jose Carmona To Be Stepping Down As CFO RTTNews

08:15AM EDT -- Organizational Changewithin Finance Function -- Creates Capital, Strategy &Transactions Group GlobeNewswire Inc

Sep 9, 2020

07:45AM EDT Radius Health, Inc. (Radius or the Company) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Virtual Meeting which will take place between September 11-15. GlobeNewswire Inc

Sep 8, 2020

08:16AM EDT Radius Health Announces Enrollment Completed For Phase 3 wearABLe trial Benzinga

08:00AM EDT -- Innovative transdermal technology enables delivery of abaloparatide molecule a peptide - across the skin -- Trial success followed by regulatory approval would provide a completely unique drug administration option for postmenopausal women with osteoporosis. -- wearABLe progress follows recent male study enrollment completion GlobeNewswire Inc

Sep 2, 2020

04:15PM EDT Radius Health, Inc.(Nasdaq: RDUS) today announced its participation in the following conferences inSeptember 2020. GlobeNewswire Inc

Aug 25, 2020

09:16AM EDT Radius Health Says TYMLOS Patent Extended To 2031; Says Enrollment Completed For ATOM Phase 3 Study Assessing The Efficacy, Safety Of Abaloparatide-SC In Males With Osteoporosis Benzinga

09:12AM EDT Radius Health Announces Business Update Including Extension Of Patent For TYMLOS RTTNews

09:00AM EDT -- TYMLOS patent extended to 2031, adding approximately 3 years to the TYMLOS-SC patent life -- Enrollment completed for ATOM Phase 3 study assessing the efficacy and safety of abaloparatide-SC in males with osteoporosis GlobeNewswire Inc

07:53AM EDT Morgan Stanley Maintains Equal-Weight on Radius Health, Lowers Price Target to $19 Benzinga

Aug 11, 2020

07:44AM EDT Citigroup Maintains Buy on Radius Health, Lowers Price Target to $25 Benzinga

Aug 10, 2020

08:44AM EDT Radius Health: Q2 Earnings Insights Benzinga

08:19AM EDT Radius Health Appoints Sean Murphy To Its Board RTTNews

08:18AM EDT Radius Health Q2 Net Loss $43.9 Mln Or $0.95/Shr Vs Loss $35.5 Mln Or $0.77/Shr Last Year RTTNews

08:15AM EDT Radius Health, Inc. (Radius or the Company) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect. GlobeNewswire Inc

08:15AM EDT TYMLOS U.S. net sales of $50 million, with 22% year over year growth GlobeNewswire Inc

08:09AM EDT Radius Health Q2 EPS $(0.95) Misses $(0.74) Estimate, Sales $50.11M Beat $48.40M Estimate Benzinga

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Jul 30, 2020

05:07PM EDT Guardant Health Reports Collaboration With Radius Health To Develop Liquid Biopsy Companion Diagnostic For Elacestrant Benzinga

Jul 27, 2020

04:15PM EDT Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update. GlobeNewswire Inc

Jul 24, 2020

04:53AM EDT SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $18 Benzinga

Jul 23, 2020

04:20PM EDT Radius Health Reports Global License Deal For Development, Commercialization Of Elacestrant With Menarini Group, Co. Will Receive $30M Upfront Payment, Up To $320M In Added Milestone Payments Benzinga

04:15PM EDT Menarini Group and Radius Health Announce Global License GlobeNewswire Inc